Back to top

Analyst Blog

Merck KGaA (MKGAF) and Columbia Laboratories, Inc. recently renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years. This agreement dates back to 1999. On May 18, 2010, the agreement between the two parties was renewed for a five-year term and was to expire in May 2015. Subsequent to the recent agreement, the term will extend to May 2020.

Columbia Labs’ Crinone is a vaginal progesterone gel which utilizes the company’s proprietary sustained-release bioadhesive technology. The product is currently approved in more than 60 countries. US Food and Drug Administration (FDA) approval was received in May 1997. Merck KGaA’s division Merck Serono has global marketing authorizations for Crinone in all countries excluding the US. Crinone faces competition from marketed products like Prometrium and Endometrin.

We note that Merck KGaA recently entered into two collaborations in March. Firstly, Merck KGaA announced a strategic deal with Nordic Bioscience Clinical Development A/S for Merck KGaA’s pipeline candidate, sprifermin (recombinant human FGF-18). Sprifermin is being developed for osteoarthritis (OA) of the knee. Secondly, the company announced a deal with Bristol-Myers Squibb (BMY - Analyst Report) for the promotion of different formulations of Glucophage (metformin hydrochloride) in China. Glucophage is used for the treatment of type II diabetes particularly in overweight patients when diet and exercise alone have failed. As per the agreement, Merck KGaA and Bristol-Myers will co-promote the drug in China and share profits.

Merck KGaA carries a Zacks Rank #3 (Hold). Currently, QLT Inc. (QLTI - Analyst Report) looks more attractive with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.00 +3.09%
SANCHEZ ENE… SN 34.18 +2.67%
THE PANTRY… PTRY 21.02 +2.09%
INTEL CP INTC 35.15 +1.88%
PIPER JAFFR… PJC 54.54 +1.70%